Buprenorphine

Generic Name: Buprenorphine

Brand Names: Subutex, Sublocade, Belbuca

Buprenorphine is a partial opioid agonist used for opioid use disorder treatment and chronic pain.

Addiction MedicinePainPartial Opioid Agonist

Drug Class

Partial Mu-Opioid Receptor Agonist

DEA Schedule

Schedule Schedule III

Pregnancy

Category C — Buprenorphine has shown adverse effects in animal reproduction studies. Buprenorphine monotherapy is often preferred over the combination buprenorphine-naloxone product during pregnancy. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not promptly recognized and treated.

Available Forms

Sublingual tablet (2 mg, 8 mg — Subutex), Buccal film (75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg, 900 mcg — Belbuca), Transdermal patch (5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, 20 mcg/hr — Butrans), Subcutaneous extended-release injection (100 mg, 300 mg monthly — Sublocade), IV/IM injection (0.3 mg/mL — Buprenex)

What It's Used For

Dosage Quick Reference

These are general dosage guidelines. Your doctor will determine the appropriate dose for your specific situation.

Condition	Starting Dose	Maintenance Dose
Opioid use disorder — induction (sublingual)	2–4 mg on Day 1 once moderate withdrawal present	Titrate to 8–24 mg/day; target 16 mg/day for most patients
Opioid use disorder — extended-release (Sublocade)	300 mg SC monthly × 2 months after sublingual stabilization	100 mg SC monthly; may continue 300 mg if needed
Chronic pain (Belbuca buccal film)	75 mcg every 12 hours (opioid-naive)	Titrate every 4 days; max 900 mcg every 12 hours
Chronic pain (Butrans patch)	5 mcg/hr patch every 7 days	Titrate every 72 hours; max 20 mcg/hr
Acute moderate-to-severe pain (IV/IM)	0.3 mg IV/IM every 6 hours as needed	Titrate to effect; monitor respiratory status

Side Effects

Common Side Effects:

Headache
Nausea and vomiting
Constipation
Sweating
Insomnia
Pain
Peripheral edema
Sedation
Application site reactions (patches)

Serious Side Effects:

Respiratory depression
Neonatal opioid withdrawal syndrome
Hepatotoxicity
Adrenal insufficiency
QT prolongation
Precipitated withdrawal
Serotonin syndrome (with serotonergic drugs)

Drug Interactions

Buprenorphine carries serious interaction risks despite its partial agonist ceiling effect on respiratory depression.

Benzodiazepines (e.g., alprazolam, clonazepam, diazepam): An FDA Boxed Warning highlights the risk of profound sedation, respiratory depression, coma, and death. Limit dose and duration if co-prescription is unavoidable, and counsel patients extensively.
Other CNS depressants (alcohol, sedating antihistamines, gabapentin, pregabalin, sleep aids): Additive CNS and respiratory depression. Counsel patients to avoid alcohol entirely and disclose all sedating medications.
CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): Increase buprenorphine plasma levels, potentially intensifying sedation. Monitor closely or reduce buprenorphine dose.
CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine): Accelerate buprenorphine metabolism, possibly precipitating withdrawal or loss of analgesia. Dose adjustment may be required.
Full opioid agonists (e.g., morphine, oxycodone, fentanyl): Buprenorphine has very high mu-receptor affinity and may displace full agonists, precipitating acute withdrawal. Conversely, full agonists taken during buprenorphine therapy may have blunted analgesic effect.
Serotonergic agents (SSRIs, SNRIs, MAOIs, triptans): May increase the risk of serotonin syndrome — monitor for agitation, hyperthermia, and clonus.

Additional Information

Buprenorphine is a partial opioid agonist used for the treatment of opioid use disorder and chronic pain management. This medication provides effective treatment for opioid dependence while having a unique pharmacological profile that limits its abuse potential and reduces overdose risk.

Mechanism of Action

Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. As a partial agonist, it produces opioid effects (analgesia, euphoria) but with a ceiling effect—increasing doses beyond a certain point do not increase effects. This ceiling effect limits respiratory depression risk compared to full agonists. Buprenorphine has very high binding affinity for mu-receptors, allowing it to displace other opioids and prevent their effects. Its slow dissociation from receptors contributes to its long duration of action. The kappa antagonism may contribute to antidepressant effects and reduced dysphoria.

Available Formulations

Buprenorphine is available in multiple formulations: sublingual tablets (2 mg, 8 mg), buccal film, transdermal patch (for pain), extended-release subcutaneous injection (monthly), and implantable rods (lasting 6 months). For opioid use disorder, sublingual and injectable formulations are preferred. The sublingual tablet must dissolve under the tongue; swallowing reduces bioavailability to approximately 15%. Transdermal patches are used for chronic pain, not addiction treatment.

Medical Uses

Buprenorphine is FDA-approved for the treatment of opioid use disorder (OUD), moderate to severe chronic pain (transdermal patch), and acute pain severe enough to require opioid analgesia (buccal film). For OUD, it reduces cravings, prevents withdrawal symptoms, and blocks the effects of other opioids. Unlike methadone, qualified physicians can prescribe buprenorphine from office-based settings, improving treatment access. It is a preferred medication for opioid use disorder due to its safety profile and effectiveness.

Dosing Guidelines

For opioid use disorder using sublingual tablets, induction typically starts at 2-4 mg, with additional doses of 2-4 mg given at intervals until withdrawal symptoms are controlled (usually 8-16 mg on day 1). Maintenance doses typically range from 16-24 mg daily. For chronic pain using transdermal patches, the starting dose is typically 5 mcg/hour, applied weekly. Buprenorphine should be initiated when the patient is in mild to moderate opioid withdrawal to prevent precipitated withdrawal. Extended-release injectable formulations provide monthly or weekly dosing options.

Important Safety Information

Buprenorphine carries a boxed warning regarding serious, life-threatening respiratory depression, especially when used with benzodiazepines or other CNS depressants, and for neonatal opioid withdrawal syndrome when used during pregnancy. Precipitated withdrawal can occur if administered to patients physically dependent on full opioid agonists who are not in withdrawal. The medication is a Schedule III controlled substance. Hepatotoxicity has been reported. Orthostatic hypotension and QT prolongation may occur.

Drug Interactions

CNS depressants (benzodiazepines, alcohol, other opioids, sedatives) may cause profound sedation, respiratory depression, and death. CYP3A4 inhibitors (ketoconazole, ritonavir) may increase buprenorphine levels. CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may decrease levels. Buprenorphine can precipitate withdrawal in patients dependent on full opioid agonists. Naltrexone will block buprenorphine effects; adequate washout periods are required when switching between medications.

Special Populations

Buprenorphine use during pregnancy can cause neonatal opioid withdrawal syndrome; however, the benefits of treatment may outweigh the risks, and methadone or buprenorphine is recommended over discontinuation for pregnant women with opioid use disorder. Buprenorphine is excreted in breast milk; breastfeeding women on stable buprenorphine doses may breastfeed with monitoring. Safety in pediatric patients has not been established for OUD. Elderly patients may require lower doses. Severe hepatic impairment requires dose adjustment; the medication should be used with caution in moderate impairment.

Frequently Asked Questions

Buprenorphine is a partial agonist with a ceiling on respiratory depression, making fatal overdose less likely than with methadone (a full agonist). Buprenorphine can be prescribed in a standard office setting, while methadone for opioid use disorder must be dispensed through federally regulated opioid treatment programs. Both are evidence-based and effective; the choice depends on individual circumstances.

Buprenorphine binds opioid receptors more tightly than most full agonists but only partially activates them. If full agonists are still occupying receptors, buprenorphine displaces them and provides less stimulation, triggering precipitated withdrawal — an abrupt, intense withdrawal syndrome. Waiting until you have mild-to-moderate withdrawal symptoms ensures most receptors are unoccupied.

Once stabilized on a steady dose, most patients can drive safely. During induction and dose changes, however, sedation and impaired reaction time are possible — avoid driving until you know how the medication affects you. Combining buprenorphine with alcohol, benzodiazepines, or other sedatives significantly impairs driving and is dangerous.

Sublocade is a once-monthly subcutaneous depot injection of buprenorphine administered by a healthcare provider. It is used for adults with moderate-to-severe opioid use disorder who have first been stabilized on transmucosal buprenorphine for at least 7 days. It eliminates daily dosing and reduces diversion risk.

Standard 5-panel and 10-panel urine drug screens do not typically detect buprenorphine because it is structurally different from morphine-derived opioids. However, specific buprenorphine assays exist and are commonly used by treatment programs to confirm adherence. Tell your prescriber and any testing entity that you are receiving prescribed buprenorphine.

Treatment duration is individualized. Many guidelines recommend at least 12 months of maintenance, and indefinite treatment is appropriate for many patients because longer durations are associated with lower relapse and overdose mortality. Tapering — when chosen — should be slow and shared decisions made with your prescriber.

Related Health Conditions

This medication is commonly used to treat or manage the following conditions:

Attention Deficit Hyperactivity Disorder (ADHD)

ADHD is a neurodevelopmental disorder marked by inattention, hyperactivity, and/or impulsivity, stemming from complex interactions between genetics, brain differences, and environmental factors, not poor parenting.

Learn More

Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.